Abstract 4426
Background
The use of immunotherapy in multiple cancer types is becoming mainstay along with next-generation sequencing (NGS) to identify potential actionable targets. We hypothesized that some immunoregulatory molecules are often found upregulated with certain gene mutations regardless of cancer subtype.
Methods
2740 TCGA patients were identified to have at least one potentially oncogenic mutation (mt) within an established 50-gene hotspot panel, including stomach/esophageal carcinoma (N = 255), skin cutaneous melanoma (N = 226), stomach adenocarcinoma (N = 163), breast invasive carcinoma (N = 143), and lung adenocarcinoma (N = 139), among others. Differential expression of 10 immunoregulatory molecules (IRM) was analyzed between mt vs. wt. To ensure observed significant associations were not confounded by tumor-type, differential IRM expression within mt-enriched tumor-types was compared to that of mt vs. wt.
Results
19/50 gene mutations were found to be significantly associated with ≥1 IRM expression. This included elevated CTLA4in CDKN2A mt (adj. p = 1.9e-9), elevated IDO1in FBXW7 mt (adj. p = 0.007), and decreased PDL1 in APCmt (adj, p = 0.02). In many, the mt effect-size was larger than that of tumor-type; e.g. head & neck carcinomas (HNSCC) are highly enriched for CDKN2Amt (OR = 4.9, p = 4.3e-9), yet CDKN2Amt are more associated with CTLA4expression than HNSCC location (t = 7.0 vs. 5.4). Similarly, FBXW7mt are more associated with high IDO1 than colorectal adenocarcinoma (CRC) (t = 4.3 vs. 0.9), and APC mt are more associated with low PDL1 (t=-4.1 vs. -3.2) than CRC. In total, 15 strong mt-gene/immune-regulator associations were identified.
Conclusions
The presented differential checkpoint expression patterns are strongly associated with mutation status and are not primarily driven by tissue type. NGS data continues to drive agnostic approvals while immunotherapeutic efforts work to replace chemotherapy providing better efficacy with milder toxicities. This data hopes to shed light on the future studies that may analyze optimization of concomitant versus sequential therapies in various genomic-driven targeted therapies combined with immunotherapy trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
NantWorks.
Disclosure
C.W. Szeto: Full / Part-time employment: NantCell. S.K. Reddy: Full / Part-time employment, Officer / Board of Directors: NantHealth. All other authors have declared no conflicts of interest.
Resources from the same session
5383 - A pilot trial to investigate the impact of a personalised self-management lifestyle programme using mobile technology on the health and wellbeing of cancer survivors
Presenter: Mary Grace Kelly
Session: Poster Display session 3
Resources:
Abstract
5084 - The BRIGHTLIGHT national survey of the impact of specialist teenage and young adult cancer care on caregivers’ information and support needs
Presenter: Rachel Taylor
Session: Poster Display session 3
Resources:
Abstract
4328 - Life beyond cancer: Occupational health care service support in returning work experienced by cancer survivals
Presenter: Minna Nurmi
Session: Poster Display session 3
Resources:
Abstract
3337 - Investigating the factors related to primary caregivers' burden in oncology patients in Greece
Presenter: Ourania Govina
Session: Poster Display session 3
Resources:
Abstract
3387 - Factors Influencing the Level of Emotional Support from Nurses Perceived by Patients Undergoing Haematopoietic Stem Cell Transplantation in Protective Isolation
Presenter: Michela Piredda
Session: Poster Display session 3
Resources:
Abstract
935 - Progressive Muscle Relaxation and Guided Imagery Techniques and the Way of Coping of Parents of Children with Malignancies: A randomized controlled trial
Presenter: Tsitsi Theologia
Session: Poster Display session 3
Resources:
Abstract
3457 - Pharmacist and Nurse Led Melanoma Immunotherapy Clinic
Presenter: Dharmisha Chauhan
Session: Poster Display session 3
Resources:
Abstract
5160 - Measuring the impact of the Irish Cancer Society's Cancer Information Services
Presenter: Aileen McHale
Session: Poster Display session 3
Resources:
Abstract
4297 - It's Great to Talk
Presenter: Noreen Andersen
Session: Poster Display session 3
Resources:
Abstract
4444 - Impact of Burn-Out Syndrome in Oncology personnel and its improvement through specific interventions
Presenter: Inmaculada Ortega
Session: Poster Display session 3
Resources:
Abstract